|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan显示文摘AIM:To evaluate the efficacy and safety of esomeprazole-based triple therapy compared with lansoprazole therapy as first-line eradication therapy for patients with Helicobacter pylori(H.pylori)in usual post-marketing use in Japan,where the clarithromycin(CAM)resistance rate is 30%.METHODS:For this multicenter,randomized,openlabel,non-inferiority trial,we recruited patients(≥20years of age)with H.pylori infection from 20 hospitals in Japan.We randomly allocated patients to esomeprazole therapy(esomeprazole 20 mg,CAM 400 mg,amoxicillin(AC)750 mg for the first 7 d,with all drugs given twice daily)or lansoprazole therapy(lansoprazole30 mg,CAM 400 mg,AC 750 mg for the first 7 d,with all drugs given twice daily)using a minimization method with age,sex,and institution as adjustment factors.Our primary outcome was the eradication rate by intention-to-treat(ITT)and per-protocol(PP)analyses.H.pylori eradication was confirmed by a urea breath test from 4 to 8 wk after cessation of therapy.RESULTS:ITT analysis revealed the eradication rates of 69.4%(95%CI:61.2%-76.6%)for esomeprazole therapy and 73.9%(95%CI:65.9%-80.6%)for lansoprazole therapy(P=0.4982).PP analysis showed eradication rate of 76.9%(95%CI:68.6%-83.5%)for esomeprazole therapy and 79.8%(95%CI:71.9%-86.0%)for lansoprazole therapy(P=0.6423).There were no differences in adverse effects between the two therapies.CONCLUSION:Esomeprazole showed non-inferiority and safety in a 7 day-triple therapy for eradication of H.pylori compared with lansoprazole. | Tsutomu Nishida Masahiko Tsujii Hirohisa Tanimura Shusaku Tsutsui Shingo Tsuji Akira Takeda Atsuo Inoue Hiroyuki Fukui Toshiyuki Yoshio Osamu Kishida Hiroyuki Ogawa Masahide Oshita Ichizo Kobayashi Shinichiro Zushi Makoto Ichiba Naoto Uenoyama Yuichi Yasunaga Ryu Ishihara Mamoru Yura Masato Komori Satoshi Egawa Hideki Iijima Tetsuo Takehara | 2014 | World Journal of Gastroenterology2014，20，15： | 13 |
| 2 | 28例中央轴空病的临床病理分析显示文摘目的探讨中央轴空病的临床病理特点及临床与病理间的关系。方法回顾性分析28例中央轴空病患者的临床及肌肉病理资料。结果28例中央轴空病病例中,22例出现明确的肢体肌无力,6例无临床症状;21例伴有骨、关节畸形;18例存在运动发育迟滞;在出生时,11例表现为松软婴儿,8例出现呼吸功能不全。所有病例在肌肉病理上均出现典型的中央轴空结构,部分病例同时出现一定量的偏心轴空以及多轴空结构;22例患者肌肉病理有明确的肌间质纤维化,与出现肌无力的患者相比,无临床症状者病理上出现相对较多的多轴空及偏心轴空,肌肉组织纤维化较轻。结论中央轴空病临床及病理表现可以有着很大的变异。 | 吴士文 马维娅 于生元 沈定国 IchizO Nishino | 2006 | 中华神经医学杂志2006，5，6： | 7 |
| 3 | Dimethyl ether fuel proposed as an alternative to LNG显示文摘 | Yoshitugi Kikkawa Ichizo Aoki | 1998 | Oil & Gas J1998，96，14： | 1 |
| 4 | Immunomodulatory effect of bovine lactoferrin pepsinhydrolysate on murine splenocytes and Peyer's patch cells显示文摘 | HIROFUMI M AKIRA K ICHIZO S | 1997 | J Dairy Sci1997，80，： | 1 |
| 5 | Modification of the single unpaired sulfhydryl group of β-lactogloblin under high pressure and the role of intermolecular S-S exchange in the pressure denaturation Single SH of β-laetogloblin and pressure denaturation 显示文摘 | Naoki T Yasuyuki T Ichizo K | 1996 | International Journal of Biological Maeromolecules1996，19，： | 1 |
| 6 | Immunomodulatory effect ofbovine lactoferrin pepsin hydrolysate on murine splenocytes and Peyer's Patch cells显示文摘 | HIROFUMI M AKIRA K ICHIZO S | 1997 | J Dairy Sci1997，80，10： | 1 |
| 7 | Dimethyl ether fuel proposed as an alternative to LNG显示文摘 | Yoshitsu K Ichizo A | 1998 | Oil Gas J1998，96，6： | 1 |
| 8 | Pilot Study of Short-Term Effects of a Novel Long-Acting Oral Beraprost in Patients With Pulmonary Arterial Hypertension显示文摘 | Daisuke Ikeda Ichizo Tsujino Shinji Sakaue | 2007 | Circ J2007，71，： | 1 |
| 9 | A rtutin increases the pigmentation of cultured human melanocytes through mechanisms other than the induction of tyrosinase activity 显示文摘 | Nitsunari Nakajima Ichizo Shinoda Yasuo Fukuwatari el al | 1998 | Pigment Cell Research1998，11，1： | 1 |
| 10 | Addition of Oral Sildenafil to Beraprost Is a Safe and Effective Therapeutic Option for Patients with Pulmonary Hypertension显示文摘 | Daisuke Ikeda Ichizo Tsujino Hiroshi Ohira Naofumi Itoh Mitsunori Kamigaki Shinji Ishimaru Shinji Sakaue Masaharu Nishimura | 2005 | Journal of Cardiovascular Pharmacology2005，，4： | 1 |
| 11 | Lysosomal myopathies: An excessive build-up in autophagosomes is too much to handle显示文摘 | May Christine Malicdan Satoru Noguchi Ikuya Nonaka Paul Saftig Ichizo Nishino | 2008 | Neuromuscular Disorders2008，，7： | 1 |
| 12 | Electrochemical selectivity for redox systems at oxygen-terminated diamond electrodes显示文摘 | ICHIZO Y HIDEO N TAKESHI K | 1999 | Journal of Electroanalytical Chemistry1999，473，12： | 1 |
| 13 | 显示文摘 | Ichizo A | 1998 | OilGas J1998，96，6： | 1 |
| 14 | Magnetic flux leakage by adjacent parallel surface slots显示文摘 | Ichizo Uetake Tetsuya Saito | 1997 | NDT & E International1997，30，6： | 1 |
| 15 | Technical efforts focdus on cutting LNG plant oosts显示文摘 | Ichizo Aoki Yoshitsugi kikkawa | 1995 | Oil & Gas Journal1995，，： | 1 |
| 16 | Arbutin Increases the Pigmentation of Cultured Human Melanocytes Through Mechanisms Other Than the Induction of Tyrosinase Activity显示文摘 | Nitsunari Nakajima Ichizo Shinoda Yasuo Fukuwatari | 1998 | Pigment Cell Research1998，11，1： | 1 |
| 17 | Dimethylthioxanthones Formed by Condensation of 2-Mercaptobenzoic Acid with o-, or w-Xylene in Sulfuric Acid (Organic, Chemical)显示文摘 | ICHIZO O MICHIO K HIDETOSHI F | 1987 | Chem Pharm Bull1987，35，6： | 1 |
| 18 | Lipid storage myopathy显示文摘 | Wen-Chen Liang Ichizo Nishino | 2011 | Curr Neurol Neurosci Rep2011，11，： | 1 |
| 19 | Hemodynamic effects of ambrisentan-tadalafil combination therapy on progressive portopulmonary hypertension显示文摘Intravenous epoprostenol is recommended for World Health Organization functional class(WHO-FC) Ⅳ patients with pulmonary arterial hypertension(PAH) in the latest guidelines. However, in portopulmonary hypertension(PoP H) patients, advanced liver dysfunction and/or thrombocytopenia often makes the use of intravenous epoprostenol challenging. Here we report the cases of two WHO-FC Ⅳ PoP H patients who were successfully treated with a combination of two oral vasodilators used to treat PAH: ambrisentan and tadalafil. Oral vasodilator therapy using a combination of ambrisentan and tadalafil may be a safe and effective therapeutic option for WHO-FC Ⅳ PoP H patients and should be considered for selected patients with severe and rapidly progressing PoP H. | Yu Yamashita Ichizo Tsujino Takahiro Sato Asuka Yamada Taku Watanabe Hiroshi Ohira Masaharu Nishimura | 2014 | World Journal of Hepatology2014，6，11： | 1 |
| 20 | Magnetic flux leakage by adjacent parallel surface slots显示文摘 | Ichizo Uetake Tetsuya Saito | 1997 | NDT&E International1997，30，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员